HK1149709A1 - Use of mva to treat prostate cancer mva - Google Patents

Use of mva to treat prostate cancer mva

Info

Publication number
HK1149709A1
HK1149709A1 HK11103921.5A HK11103921A HK1149709A1 HK 1149709 A1 HK1149709 A1 HK 1149709A1 HK 11103921 A HK11103921 A HK 11103921A HK 1149709 A1 HK1149709 A1 HK 1149709A1
Authority
HK
Hong Kong
Prior art keywords
mva
prostate cancer
treat prostate
recombinant mva
mva viruses
Prior art date
Application number
HK11103921.5A
Other languages
English (en)
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Ryan Blair Rountree
Fatema Legrand
Original Assignee
Bavarian Nordic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic Inc filed Critical Bavarian Nordic Inc
Publication of HK1149709A1 publication Critical patent/HK1149709A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194Prostate specific antigen [PSA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/04Uses of viruses as vector in vivo
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11103921.5A 2007-10-18 2011-04-19 Use of mva to treat prostate cancer mva HK1149709A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96089307P 2007-10-18 2007-10-18
PCT/US2008/080229 WO2009052328A1 (en) 2007-10-18 2008-10-16 Use of mva to treat prostate cancer

Publications (1)

Publication Number Publication Date
HK1149709A1 true HK1149709A1 (en) 2011-10-14

Family

ID=40342626

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103921.5A HK1149709A1 (en) 2007-10-18 2011-04-19 Use of mva to treat prostate cancer mva

Country Status (14)

Country Link
US (2) US7867483B2 (zh)
EP (1) EP2207564B1 (zh)
JP (1) JP5669581B2 (zh)
KR (2) KR101648087B1 (zh)
CN (1) CN101888853B (zh)
AU (1) AU2008312444B2 (zh)
CA (1) CA2702586C (zh)
DK (1) DK2207564T3 (zh)
ES (1) ES2608604T3 (zh)
HK (1) HK1149709A1 (zh)
IL (1) IL204541A (zh)
NZ (2) NZ584042A (zh)
RU (1) RU2499606C2 (zh)
WO (1) WO2009052328A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
CN100537773C (zh) * 2000-11-23 2009-09-09 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US20100291113A1 (en) * 2007-10-03 2010-11-18 Cornell University Treatment of Proliferative Disorders Using Antibodies to PSMA
CA2702586C (en) * 2007-10-18 2017-08-01 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
RU2673908C2 (ru) 2009-12-02 2018-12-03 Имэджинэб, Инк. Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
JP6312141B2 (ja) 2012-03-30 2018-04-18 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
KR102006527B1 (ko) 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
AU2015317370A1 (en) 2014-09-19 2017-03-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CA2994951A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3413927A4 (en) * 2016-02-12 2019-11-27 Madison Vaccines Inc. CANCER THERAPY
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
WO2017188287A1 (ja) * 2016-04-26 2017-11-02 大日本住友製薬株式会社 置換プリン誘導体
CA3026342A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CN116458475A (zh) 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
CN106084027A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3980071A4 (en) * 2019-06-07 2023-10-11 Oregon Health & Science University TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T-CELL REACTIONS
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009052A2 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288048B6 (cs) * 1991-07-25 2001-04-11 Idec Pharmaceuticals Corporation Farmaceutická kompozice k indukci cytotoxické odpovědi T-lymfocytů
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
WO1998004689A1 (en) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP0973916A1 (en) * 1997-04-11 2000-01-26 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
NZ511055A (en) * 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination
DE69936061T2 (de) * 1998-12-09 2008-01-17 Therion Biologics Corp., Cambridge Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
CN100537773C (zh) * 2000-11-23 2009-09-09 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
WO2003073828A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
JP4895505B2 (ja) * 2002-05-16 2012-03-14 バヴァリアン・ノルディック・アクティーゼルスカブ 変異ワクシニアウイルスアンカラ(mva)ゲノム中の挿入部位としての遺伝子間領域
JP2007502602A (ja) * 2003-08-21 2007-02-15 バイラックス・ディベロップメント・プロプライエタリー・リミテッド 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター
BRPI0401465A (pt) 2004-04-20 2006-02-21 Embria Informatica Ltda sistema para administrar interações entre usuários e aplicações de software em um ambiente web
CA2702586C (en) 2007-10-18 2017-08-01 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer

Also Published As

Publication number Publication date
EP2207564A1 (en) 2010-07-21
KR20160065985A (ko) 2016-06-09
JP5669581B2 (ja) 2015-02-12
CN101888853B (zh) 2013-03-13
US7867483B2 (en) 2011-01-11
US8377688B2 (en) 2013-02-19
CN101888853A (zh) 2010-11-17
KR101648087B1 (ko) 2016-08-17
NZ584042A (en) 2012-09-28
US20090104225A1 (en) 2009-04-23
ES2608604T3 (es) 2017-04-12
CA2702586C (en) 2017-08-01
IL204541A (en) 2015-02-26
WO2009052328A8 (en) 2009-07-02
CA2702586A1 (en) 2009-04-23
KR20100109545A (ko) 2010-10-08
IL204541A0 (en) 2010-11-30
US20110008386A1 (en) 2011-01-13
WO2009052328A1 (en) 2009-04-23
RU2010115220A (ru) 2011-11-27
NZ601827A (en) 2014-01-31
AU2008312444B2 (en) 2014-02-06
JP2011500718A (ja) 2011-01-06
AU2008312444A1 (en) 2009-04-23
RU2499606C2 (ru) 2013-11-27
DK2207564T3 (en) 2017-01-16
EP2207564B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
HK1149709A1 (en) Use of mva to treat prostate cancer mva
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
WO2008045346A3 (en) Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
MX346924B (es) Compuestos de diarilhidantoina.
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
MY191825A (en) Therapeutic compounds and compositions
MY162903A (en) Methods of treatment of pancreatic cancer
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
WO2008030883A3 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191010